マダガスカルの学童における腸内細菌叢と鉄状態へのコオロギおよびブラックソルジャーフライ幼虫強化クラッカーの影響
マダガスカルの学童における腸内細菌叢および鉄状態へのクリケットとブラックソルジャーフライ幼虫強化クラッカーの影響
The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.
Specifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).
調査の概要
状態
詳細な説明
Food insecurity, child malnutrition, and anemia remain significant public health problems globally, including in Madagascar where 40% of children under 5 years of age are chronically malnourished (stunted), 8% are wasted, and 46% are anemic (DHS, 2021). Interventions aimed at addressing this have often foundered on the fact that the foods that would address these nutrient deficiencies are physically unavailable, too expensive for poor households to purchase, or contribute to climate change or environmental degradation. Consequently, there is interest in the development of novel food products that could contribute to reducing malnutrition in all its forms, without the drawbacks of relying on existing food products. One possibility is to develop food products based on insects. Edible insects are low-cost, climate friendly, with nutritional profiles akin to meat. They contain high amounts of protein, iron, and zinc while also providing a novel source of prebiotic fiber. It is hypothesized that insect-based foods could improve children's health outcomes as measured by gut inflammation, anemia, and growth. The investigators and others have developed an insect-fortified cracker snack, suitable for the nutritional requirements of school-age children living in Southeast Madagascar. The investigators have already assessed the product's nutrient profile. They also have documented the safety tests done to date; these show that the snack is safe for human consumption. The test results have been submitted to the Malagasy regulatory authority for registering food and health products and the government has approved the insect powders as food for human consumption and issued "Certificates for Human Consumption". The investigators have also conducted an acceptability trial that showed that child participants like the organoleptic characteristics of the crackers and regularly consume the crackers in biologically meaningful quantities.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Vakinankaratra Region
-
Antsirabe、Vakinankaratra Region、マダガスカル
- FSRP Sschools
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria for children
- Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools
- Caregiver or legal guardian is willing to provide informed consent
- Child is willing to provide informed assent
Exclusion criteria for children
- Child age is outside the preferred age range (9 to 13 years)
- Not enrolled in the participating schools
- Unable or unwilling to comply with the study requirements
- Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g/dL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.
- Covid-exposure or symptoms: loss of smell or taste
- History of food allergies or adverse reactions to any edible insects
- Chronic severe medical condition or congenital anomalies requiring frequent medical attention or interfering with dietary consumption
- Caregiver does not give consent, or child does not assent
Inclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)
Exclusion criteria for parents
• Caregiver does not consent to participate
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment
Consumption of insect-fortified (crickets and black soldier fly larvae) crackers. |
Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.
他の名前:
|
|
プラセボコンパレーター:Control
Consumption of rice and corn crackers |
Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Gut mircrobiome
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess gut microbiome composition at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through 16S rRNA sequencing and quantification of fecal biomarkers. |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Iron via soluble transferrin receptor
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through soluble transferrin receptor (mg/L). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via calprotectin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: calprotectin (µg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via lactoferrin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lactoferrin (µg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via lipocalin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lipocalin (ng/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via anlpha-1 antitrypsin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: anlpha-1 antitrypsin (mg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Intestinal inflammation via myeloperoxidase
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: myeloperoxidase (µg/g). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Systemic inflammation via quantification of circulating cytokines
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will also assess systemic inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through quantification of circulating cytokines, including IL-1β, IL-2, IL-4, IL-6, IL-10, IL-22, TNF-α, IFN-γ, CCL2, all expressed as pg/mL. |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Iron via quantification of hemoglobin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through quantification of hemoglobin (g/dL). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
|
Iron via inflammation adjusted ferritin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through inflammation adjusted ferritin (µg/L). |
From enrollment to the end of treatment after 14 weeks of cracker consumption.
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:John Hoddinott, DPhil、Cornell University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- IRB0149913
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD 共有時間枠
July 2026 to July 2027
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。